| Literature DB >> 28811831 |
Aranya Manosroi1,2,3, Theeraphong Tangjai3,4, Charinya Chankhampan1,2,3, Worapaka Manosroi5, Yaravee Najarut1, Worapong Kitdamrongtham1,2, Jiradej Manosroi1,2,3.
Abstract
Seven plants in the top rank were selected from the "MANOSROI III" database using the two Thai keywords which meant impotence and sexual tonic. Boesenbergia rotunda (L.) Mansf. extract [EDP1-001(1)] gave the highest PDE inhibition activity of 4.36-fold sildenafil, a standard anti-impotence drug. Plumbago indica Linn. extract [EDP2-001(1)] exhibited the highest NO release stimulation activity of 666.85% which was 1.50-fold acetylcholine, a standard drug. Most selected plant extracts were nontoxic to EA.hy926 cells at 1.0 mg/mL. EDP1-001(1) exhibited the LD50 value of acute oral toxicity in male ICR mice of over 5,000 mg/kg body weight. EDP1-001(1) also indicated the improvement of sexual behaviors in the paroxetine-induced sexual dysfunction male mice with the evaluation of number of courtships (NC), mount frequency (MF), intromission frequency (IF), and ejaculatory frequency (EF) at 87.67 ± 6.17, 121.00 ± 23.50, 36.00 ± 3.21, and 13.67 ± 2.96 which were 2.63-, 1.27-, 0.53-, and 0.62-fold sildenafil-treated mice at day 14 of the treatments, respectively. The present study has not only confirmed the traditional use of Thai plants for the treatment of ED but also indicated the potential and application of the "MANOSROI III" database for Thai plant selection to be developed as ED food supplements.Entities:
Year: 2017 PMID: 28811831 PMCID: PMC5547717 DOI: 10.1155/2017/9806976
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Seven medicinal plants selected from the Thai medicinal plant recipe database “MANOSROI III” and their extracts.
| Number | Medicinal plants | Preparation of the extracts | ||||||
|---|---|---|---|---|---|---|---|---|
| Code | Botanical name | Family | Part used | Recipe preparation indication | Extract code | % yield (w/w) | Physical appearance of the extracts | |
| 1 | EDP1-001 |
| Zingiberaceae | Rhizome | A | EDP1-001(1) | 10.80 | Brown, slightly viscous semisolid |
| B | EDP1-001(2) | 8.15 | Light brown, powder | |||||
| D | EDP1-001(3) | 6.85 | Brown, slightly viscous semisolid | |||||
|
| ||||||||
| 2 | EDP1-002 |
| Piperaceae | White seed | A | EDP1-002(1) | 2.55 | Dark brown, viscous semisolid |
| B | EDP1-002(2) | 1.45 | Light brown, powder | |||||
|
| ||||||||
| 3 | EDP1-003 |
| Ebenaceae | Whole | A | EDP1-003 | 6.60 | Dark brown, viscous semisolid |
|
| ||||||||
| 4 | EDP1-004 |
| Piperaceae | Black seed | A | EDP1-004 | 4.30 | Dark brown, viscous semisolid |
|
| ||||||||
| 5 | EDP2-001 |
| Plumbaginaceae | Whole | A | EDP2-001(1) | 22.90 | Dark brown, slightly viscous semisolid |
| C | EDP2-001(2) | 26.60 | Dark brown, viscous semisolid | |||||
| D | EDP2-001(3) | 24.20 | Red-brown, slightly viscous semisolid | |||||
|
| ||||||||
| 6 | EDP2-002 |
| Piperaceae | Black seed | C | EDP2-002(1) | 5.60 | Dark brown, slightly viscous semi-solid |
| D | EDP2-002(2) | 5.20 | Dark brown, slightly viscous semisolid | |||||
|
| ||||||||
| 7 | EDP2-003 |
| Piperaceae | Whole | A | EDP2-003(1) | 16.30 | Dark brown, slightly viscous semisolid |
| B | EDP2-003(2) | 6.45 | Dark brown, slightly viscous semisolid | |||||
| D | EDP2-003(3) | 15.00 | Red-brown, viscous semisolid | |||||
Method A: the recipes were orally administered together with honey or molded as traditional pills. Method B: the recipes were boiled with water. Method C: the recipes were used as an infusion. Method D: the recipes were orally administered as a herbal liquor.
Phosphodiesterases (PDEs) inhibition and nitric oxide (NO) release stimulation activities of the fifteen selected plant extracts.
| Number | Samples | Inhibition of PDEs activity | Stimulation of NO release | ||||||
|---|---|---|---|---|---|---|---|---|---|
| % | IC50 (mg/mL) | % | SC50 (mg/mL) | ||||||
| Mean ± S.D. | Folds of sildenafil | Mean ± SD | Folds of sildenafil | Mean ± SD | Folds of acetylcholine | Mean ± SD | Folds of acetylcholine | ||
| 1 | EDP1-001(1) | 65.28 ± 2.09 | 4.36 | 0.0026±0.0025 | 2.23 | 100.17 ± 11.24 | 0.23 | 3.96 ± 5.57 | 0.002 |
| 2 | EDP1-001(2) | 10.35 ± 5.22 | 0.69 | — | — | 33.53 ± 12.69 | 0.08 | — | — |
| 3 | EDP1-001(3) | −667.44 ± 64.76 | −44.61 | — | — | 129.99 ± 49.70 | 0.29 | — | — |
| 4 | EDP1-002(1) | −22.22 ± 10.03 | −1.49 | — | — | 122.37 ± 27.91 | 0.28 | — | — |
| 5 | EDP1-002(2) | 63.74 ± 2.28 | 4.26 | — | — | −104.10 ± 5.80 | −0.23 | — | — |
| 6 | EDP1-003 | 8.77 ± 5.14 | 0.59 | — | — | 162.45 ± 19.57 | 0.37 | 0.49 ± 0.33 | 0.016 |
| 7 | EDP1-004 | −42.75 ± 8.01 | −2.86 | — | — | 275.00 ± 39.08 | 0.62 | — | — |
| 8 | EDP2-001(1) | 2.72 ± 4.82 | 0.18 | — | — | 666.85 ± 24.66 | 1.50 | — | — |
| 9 | EDP2-001(2) | 7.24 ± 6.71 | 0.48 | — | — | 312.13 ± 4.36 | 0.70 | — | — |
| 10 | EDP2-001(3) | −16.77 ± 10.69 | −1.12 | — | — | 179.03 ± 11.01 | 0.40 | — | — |
| 11 | EDP2-002(1) | −47.40 ± 6.74 | −3.17 | — | — | −133.32 ± 7.90 | −0.30 | — | — |
| 12 | EDP2-002(2) | −34.06 ± 4.02 | −2.28 | — | — | 277.27 ± 82.65 | 0.63 | — | — |
| 13 | EDP2-003(1) | −2.20 ± 3.72 | −0.15 | — | — | −60.79 ± 9.07 | −0.14 | — | — |
| 14 | EDP2-003(2) | 44.02 ± 2.49 | 2.94 | — | — | −110.76 ± 34.08 | −0.25 | — | — |
| 15 | EDP2-003(3) | −3.81 ± 2.08 | −0.25 | — | — | −115.38 ± 23.21 | −0.26 | — | — |
|
| |||||||||
| 16 | Sildenafil | 14.96 ± 8.39 | 1 | 0.0058 ± 0.0032 | 1 | — | — | — | — |
|
| |||||||||
| 17 | Acetylcholine | — | — | — | — | 443.63 ± 91.94 | 1 | 0.008 ± 0.003 | 1 |
|
| |||||||||
| 18 | L-NAME | — | — | — | — | −85.12 ± 10.47 | −0.19 | −38.10 ± 16.96 | −0.0002 |
Inhibition of PDEs activity: inhibition percentages were determined at the concentrations of the extracts and sildenafil at 200 and 0.45 µg/mL, respectively. IC50 was the concentrations of samples giving 50% inhibition of the PDEs activity. The minus value indicated the stimulation of PDEs. Stimulation of NO release: stimulation percentages of the extracts, acetylcholine, and L-NAME were tested at the concentration of 1 mg/mL. SC50 was the concentrations of samples giving 50% stimulation of the NO production activity. L-NAME was N-nitro-L-arginine methyl ester hydrochloride (NO release inhibitor). The minus value indicated the inhibition of NO production.
Figure 1Cell viability of EA.hy926 treated with the 15 selected plant extracts at 1.0 mg/mL [% cell viability = (A540 of the sample/A540 of the control) × 100, where A540 was the absorbance at 540 nm and the control was the untreated cells].
Phytochemicals of the selected plant extracts.
| Phytochemical contents | Extracts | |
|---|---|---|
| EDP1-001(1) | EDP1-003 | |
| Alkaloids | — | + |
| Anthraquinones | — | — |
| Carotenoids | — | — |
| Flavonoids | +++ | — |
| Glycosides | — | — |
| Saponins | +++ | — |
| Tannins | — | — |
| Xanthones | — | + |
+++: abundant presence, +: slight presence; —: absence.
Figure 2HPLC fingerprint of the EDP1-001(1) extract at 100 mg/ml (a) which exhibited the peak of flavone at the retention time of 10.345 min with the content of 58 µg/mg extract and HPLC fingerprint of the standard flavone at 1 mg/ml (b).
Body and organ weights of the male mice (n = 5) after being orally given the EDP1-001(1) extract at the single dose of 5,000 mg/kg body weight.
| Samples | Body weight (g) | Organ weights (g) at day 14 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before | Day 14 | Heart | Lung | Liver | Spleen | Kidneys | Stomach | Intestine | Testis | |
| EDP1-001(1) | 38.33 ± 2.58 | 47.10 ± 2.37 | 0.29 ± 0.03 | 0.36 ± 0.02 | 2.80 ± 0.18 | 0.16 ± 0.05 | 0.85 ± 0.04 | 0.34 ± 0.04 | 4.01 ± 0.66 | 0.32 ± 0.03 |
| Water (control) | 41.60 ± 2.58 | 41.67 ± 2.58 | 0.28 ± 0.03 | 0.42 ± 0.04 | 2.39 ± 0.20 | 0.15 ± 0.02 | 0.91 ± 0.07 | 0.36 ± 0.05 | 3.10 ± 0.29 | 0.34 ± 0.04 |
Significant difference (p < 0.05) in comparison to the control group.
Sexual behavior stimulatory effects on numbers of courtship and mount frequency in paroxetine-induced sexual dysfunction male mice (n = 3) after daily oral administration of the EDP1-001(1) extract for 1, 7, and 14 days.
| Day | Numbers of courtship | Mount frequency | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Distilled water | Sildenafil | EDP1-001(1) extract | Distilled water | Sildenafil | EDP1-001(1) extract | |||||
| Number | Fold1 | Fold2 | Frequency | Fold1 | Fold2 | |||||
| 1 | 16.00 ± 4.62 | 56.00 ± 5.69 | 12.33 ± 7.84 | 0.77 | 0.22 | 28.33 ± 14.43 | 79.67 ± 46.19 | 16.33 ± 10.48 | 0.58 | 0.01 |
| 7 | 18.33 ± 3.76 | 27.00 ± 17.09 | 26.33 ± 3.48 | 1.44 | 0.98 | 1.00 ± 1.00 | 101.00 ± 2.08 | 17.00 ± 12.34 | 17.00 | 0.17 |
| 14 | 15.67 ± 2.85 | 33.33 ± 2.73 | 87.67 ± 6.17 | 5.60 | 2.63 | 1.33 ± 0.88 | 95.33 ± 4.41 | 121.00 ± 23.50 | 90.75 | 1.27 |
Fold1 was calculated by comparing with the control group (orally administered with distilled water). Fold2 was calculated by comparing with the positive control group (orally administered with sildenafil).
Sexual behavior stimulatory effect on intromission frequency and ejaculatory frequency in paroxetine-induced sexual dysfunction male mice (n = 3) after daily oral administration of the EDP1-001(1) extract for 1, 7, and 14 days.
| Day | Intromission frequency | Ejaculatory frequency | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Distilled water | Sildenafil | EDP1-001(1) extract | Distilled water | Sildenafil | EDP1-001(1) extract | |||||
| Frequency | Fold1 | Fold2 | Frequency | Fold1 | Fold2 | |||||
| 1 | 18.00 ± 11.36 | 65.67 ± 43.53 | 4.67 ± 1.00 | 0.26 | 0.07 | 1.33 ± 1.33 | 7.33 ± 4.67 | 0 | 0 | 0 |
| 7 | 0 | 64.67 ± 24.13 | 1.00 ± 0.58 | — | 0.02 | 0 | 16.00 ± 8.50 | 0 | — | 0 |
| 14 | 0.33 ± 0.33 | 68.33 ± 16.05 | 36.00 ± 3.21 | 109.09 | 0.53 | 0 | 22.00 ± 2.52 | 13.67 ± 2.96 | — | 0.62 |
Fold1 was calculated by comparing with the control group (orally administered with distilled water); Fold2 was calculated by comparing with the positive control group (orally administered with sildenafil).